Re:GlaxoSmithKline makes $300M investment in 23andMe, forms ...
by HarryHirsch on Wednesday July 25, 2018 @03:28PM
(#17612060)
The insurance carrier has a conflict of interest. Over in Europe they have public bodies issuing treatment guidelines, but that would be a political impossibility in the US.
[ Parent
| on HN ]
Re:GlaxoSmithKline makes $300M investment in 23andMe, forms ...
by SmellyGeekBoy on Thursday July 26, 2018 @06:29AM
(#17616359)
As far as I know the UK is in Europe, and my father has recently been denied cancer treatment by multiple providers due to a low probability of success. That's by the NHS and a few private providers. The argument is that he'll have a better quality of life if he doesn't spend the rest of the time he has left going through pointless treatments that won't help anyway, an argument our family didn't initially accept but are certainly coming to terms with.
Re:GlaxoSmithKline makes $300M investment in 23andMe, forms ...
by refurb on Wednesday July 25, 2018 @04:00PM
(#17612290)
How is it any different in Europe? They make the exact same decisions.
US insurance companies use treatment guidelines issued by organizations like NCCN (oncology). If they stray too far, they get dinged for not meeting "medical necessity" requirements.
If anything, you're more likely to get an experimental cancer drug in the US than Europe since US insurance companies don't like bad press.